anna caldwell, Author at European Medical Journal - Page 7 of 16

Latest Census Exposes Consultant Psychiatrist Shortage in England

One in seven consultant psychiatrist posts are vacant across England, leading to barriers to vital care for patients with mental illness.

Novo Nordisk launches higher-dose semaglutide

Novo Nordisk has launched a 7.2 mg semaglutide injection in the US, following FDA approval on 19 March.

Fertility-Inducing Medications May Increase Melanoma Risk

Among infertile women, those treated with fertility-inducing medications face an increased melanoma risk, according to a 2026 systematic review and meta-analysis.

Binge Drinking Once a Month May Triple Liver Fibrosis Risk

Patients with MASLD who binge drink, even once a month, face a threefold higher risk of advanced liver fibrosis.

ASCVD costs global health industry $680bn annually

Atherosclerotic cardiovascular disease costs the equivalent of Sweden’s entire economy, a new report has revealed.

Lifestyle Interventions Effective in Prostate Cancer Radiotherapy

Nutrition and lifestyle interventions are promising for improving the quality of life of patients with prostate cancer undergoing radiotherapy, a 2026 review has concluded.

AI Uses Eye-Tracking Technology to Diagnose Autism

AI can distinguish children with autism spectrum disorder using eye-tracking technology with an accuracy of 85%, a 2026 systematic review has found.

More Than One Million People to be Offered Semaglutide on NHS

Semaglutide is set to be offered to more than one million people with cardiovascular disease on the NHS in coming months.

Eli Lilly office building

Lilly’s weight loss pill wins FDA approval

Eli Lilly won FDA approval on 1 April 2026 for a once-daily oral GLP-1, orforglipron.

Integrated Genomic Model Improves CAD Risk Prediction

The model identified approximately 13% of high-risk individuals who would not have been detected using polygenic risk scores alone.